cached image

Philip Scheltens, MD PhD

Alzheimer Center VU University Medical Center, Amsterdam, Netherlands 
dementia, MRI, CSF, PET,
"Philip Scheltens"

Cross-listing: Neurotree


Sign in to add mentor
Johan Carel Koetsier grad student 1993 VU Amsterdam (Neurotree)
Jaap Valk grad student 1993 VU Amsterdam (Neurotree)
 (MR imaging in Alzheimer's disease)


Sign in to add trainee
Koene R.A. Van Dijk grad student 2001-2005 VU Amsterdam (Neurotree)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Mank A, van Maurik IS, Bakker ED, et al. (2021) Identifying relevant outcomes in the progression of Alzheimer's disease; what do patients and care partners want to know about prognosis? Alzheimer's & Dementia (New York, N. Y.). 7: e12189
Tijms BM, Gobom J, Teunissen C, et al. (2021) CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. Proteomes. 9
Vijverberg EGB, Axelsen TM, Bihlet AR, et al. (2021) Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD-VIVIAD. Alzheimer's Research & Therapy. 13: 142
Eikelboom WS, van den Berg E, Singleton EH, et al. (2021) Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations. Neurology
Ulugut H, Dijkstra AA, Scarioni M, et al. (2021) Right temporal variant frontotemporal dementia is pathologically heterogeneous: a case-series and a systematic review. Acta Neuropathologica Communications. 9: 131
Babapour Mofrad R, Scheltens P, Kim S, et al. (2021) Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status. Alzheimer's Research & Therapy. 13: 133
Ossenkoppele R, Reimand J, Smith R, et al. (2021) Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers. Embo Molecular Medicine. e14398
Ulugut H, Stek S, Wagemans LEE, et al. (2021) The natural history of primary progressive aphasia: beyond aphasia. Journal of Neurology
Wolters EE, Papma JM, Verfaillie SCJ, et al. (2021) [18F]Flortaucipir PET Across Various Mutations in Presymptomatic and Symptomatic Carriers. Neurology
Florentinus-Mefailoski A, Bowden P, Scheltens P, et al. (2021) The plasma peptides of Alzheimer's disease. Clinical Proteomics. 18: 17
See more...